Autologous CAR-T Cell Manufacturing: Current Standing and Future Directions
A Look at What Drug Manufacturers are Likely Using to Make CAR-T Products
Supplement: MilliporeSigma Sees Opportunity in Continuous Processing
From the GEN Sounds of Science Podcast
Why CAR-T Therapies Don’t Work for Everyone Yet
Selecting the Best Type of T Cells for CAR-T May be Key to the Overall Efficacy of the Therapies
Cell-Centered: Scientists Embrace Cell-Replacement Therapy for Type 1 Diabetes
Forming Beta Cells from Stem Cells
For full access to this article login to GEN Select now.
Plant Expression Systems Growing Rapidly
Use of the Technology for Vaccine Manufacture Leads the Way Toward Commercialization
- Most biotech professionals are aware that plant-based expression systems hold promise for cost-effective commercial-scale manufacture of recombinant proteins. But relatively few realize how near commercialization many of these are. With truly global, one-billion-doses-per-year-scale manufacturing facilities now under construction for influenza virus and other vaccine manufacture, these products have the ...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
Get GEN Select Access Now
- Do not put any letters or characters here if you are not a spy program.